Top executives from across the medtech industry gathered at the J.P. Morgan Healthcare Conference in San Francisco this week to offer a look at their expectations for the year ahead.
Among those presenting, Medtronic CEO Geoff Martha outlined multiple growth drivers in the pipeline, zeroing in on pulsed field ablation (PFA), renal denervation, neuromodulation and automated insulin delivery.
Dexcom CEO Kevin Sayer gave an update on the company’s first over-the-counter glucose sensor and plans to expand coverage of devices for people with Type 2 diabetes. Boston Scientific CEO Mike Mahoney told investors the company’s PFA launch is rapidly increasing its share of the electrophysiology market, while Intuitive Surgical CEO Gary Guthart shared surgeon feedback on the rollout of the new da Vinci 5 robot.
Check out MedTech Dive’s coverage of the conference here:
